By Josh BeckermanAltamira Therapeutics Ltd. shares rose 45% to $1.91 on Wednesday after it reported favorable clinical trial results for AM-125 in surgery-induced acute vestibular syndrome, a type of vertigo. The company said the Phase 2 trial "demonstrates proof of concept and shows good tolerability." The trial enrolled 124 patients who had AVS following surgery for the removal of a tumor.

Source: Wall Street Journal April 13, 2023 04:55 UTC